WEBULL
WebtradeDownload

Bristol Myers Squibb (BMY) Stock May Be 49% Undervalued Despite Phase 3 Wins

Simply Wall St · 2d ago

Bristol-Myers Squibb has delivered a 43.8% gain over the past year, and with the stock recently closing at US$61.12, the question for you is whether that move lines up with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available on the stock, the spotlight turns to what those projected cash streams really say about today’s price tag.

  • Bristol-Myers Squibb’s 43.8% 1 year return puts recent shareholders in a strong position and raises the stakes on whether the current valuation is still grounded in its underlying cash flows.
  • Fresh phase 3 successes for RYZ101, admilparant and the Zenbexus combination may support expectations for future oncology and lung disease cash flows. They also concentrate more of the investment case on how reliably those experimental therapies can turn into durable earnings.
  • What if you looked at Bristol-Myers Squibb through its earnings instead? See what Bristol-Myers Squibb's 13.5x P/E says about the price.

The issue now is whether Bristol-Myers Squibb’s recent share price level is adequately supported by the intrinsic value suggested by its cash flows under the Discounted Cash Flow (DCF) framework.

If you want to pressure test whether Bristol-Myers Squibb’s cash flow story and 43.8% 1 year return line up with its price, it helps to compare that question across 33 high quality undervalued stocks.

Does Bristol-Myers Squibb Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach links today’s valuation to the cash Bristol-Myers Squibb is expected to generate for shareholders over time. In this model, the group’s latest twelve month free cash flow is about $11.5b, with projections assuming free cash flow that is broadly stable to slightly declining over the coming decade, rather than showing aggressive expansion.

Those cash flow assumptions still lead the Discounted Cash Flow (DCF) model to an estimated intrinsic value that is substantially above the current share price of US$61.12. Positive phase 3 readouts for RYZ101, admilparant and the Zenbexus combination help explain why the cash flow forecasts remain resilient even as the market reacts in a more cautious way to pipeline news. This gap between what the cash flows support and where the equity trades is what the detailed model is designed to help you quantify. Find out what Bristol-Myers Squibb could be worth using our Discounted Cash Flow (DCF) estimate.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bristol-Myers Squibb pick up where the DCF puzzle leaves off and explain which expectations for growth, profitability and earnings would need to hold for the shares to be worth materially more or less than today’s price, all hosted on the Community page. Each one presents Bristol-Myers Squibb’s implied fair value as a thesis about how the business might perform over time, so you can see how that view holds up as new information arrives.

Bristol-Myers Squibb now splits the community between those who see a discounted oncology and AI story and those who focus on patent and pipeline risk already reflected in the price.

Bull case: 25% undervalued

"Company wide use of AI in research and enterprise operations, supported by partnerships with Anthropic and NVIDIA and tied to a formal process for earlier go or no go decisions..."

Discover why this Narrative puts Bristol-Myers Squibb at 25% undervalued.

Bear case: 30% overvalued

"While Bristol-Myers Squibb is repositioning its cardiovascular franchise around milvexian, the delay of the pivotal atrial fibrillation trial into Q1 2027 extends the period of uncertainty..."

Explore why this Narrative puts Bristol-Myers Squibb at 30% overvalued.

Before deciding what Bristol-Myers Squibb is worth, consider who is at the wheel

The cash flow story only goes so far if the people allocating that cash and setting priorities are not aligned with you, so the next step is understanding how leadership is evaluated and rewarded. See who runs Bristol-Myers Squibb and how they are paid.